Clearside Biomedical Inc at Piper Sandler Healthcare Conference Transcript
Hi, everyone. My name is Albert Lowe. I'm from the Piper Sandler biotech team. And it's my pleasure to welcome the team from Clearside Biomedical, and here to present the latest update on their unique delivery system to deliver therapy to the back of the eye using the suprachoroidal space is the CSO (sic -- Chief Medical Officer), Tom Ciulla. So, I'll hand it over. Thank you.
Thank you, Albert, and thank you to Piper Sandler for having us here today. I'd like to remind you that I'm going to make some forward-looking statements. Our risks as summarized on this slide, and of course, on our website where you can download our SEC filings.
Clearside is developing and delivering treatments that restore and preserve vision for serious back of the eye disorders. We have a versatile therapeutic platform with our SCS Microinjector with proprietary drug formulations that target suprachoroidal space. We have a two-pronged
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |